{"prompt": "['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', 'Table 5:', 'Clinical Laboratory Assessments', 'Hematology', 'Hematocrit', 'Neutrophils, absolute and %', 'Hemoglobin', 'Lymphocytes, absolute and %', 'RBC count', 'Monocytes, absolute and %', 'WBC count', 'Eosinophils, absolute and %', 'Mean corpuscular volume', 'Basophils, absolute and %', 'Mean corpuscular hemoglobin', 'Platelet count', 'CD4 in HIV-positive patients', 'Mean corpuscular hemoglobin concentration', '(at Screening only)', 'Serum Chemistry', 'Sodium', 'Potassium', 'BUN', 'Phosphate', 'Creatinine and eGFR (using the MDRD formula)', 'Albumin', 'Glucose', 'Calcium', 'Chloride', 'Carbon dioxide', 'Liver Function Tests (LFTs)', 'AST', 'ALP', 'ALT', 'Bilirubin (total and direct)', 'GGT', 'Coagulation', 'Prothrombin time', 'Activated partial thromboplastin time', 'INR', 'Fibrinogen', 'D-dimer', 'Prothrombin fragment 1, 2', 'Factor Activity', 'FVIII activity for patients with hemophilia A', 'FIX activity for patients with hemophilia B', 'Urinalysis', 'Visual inspection for appearance and color', 'Bilirubin', 'pH (dipstick)', 'Nitrite', 'Specific gravity', 'RBCs', 'Ketones', 'Urobilinogen', 'Glucose', 'Leukocytes', 'Protein', 'Microscopy (if clinically indicated)', 'Property of the Sanofi Group - strictly confidential', '58', '(electronic 1.0)']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', 'Table 5:', 'Clinical Laboratory Assessments', 'Thrombophilia Screening', 'Protein C deficiency', 'Protein S deficiency', 'Factor V Leiden (genetic testing)', 'Prothrombin mutation (genetic testing)', 'Hepatic Tests', 'Hepatitis C, including:', 'Hepatitis A, including:', 'HCV antibody', 'HAV antibody IgM and IgG', 'HCV RNA PCR - qualitative and quantitative', 'assays', 'Hepatitis B, including:', 'Hepatitis E, including:', 'HBs Ag, anti-HBc antibody, IgM and IgG', 'HEV antibody IgM and IgG', 'Immunogenicity', 'Antidrug Antibodies', 'Note: All assessments will be measured in the central laboratory.', 'Abbreviations: ALP=alkaline phosphatase; ALT=alanine transaminase; AST=aspartate transaminase; BUN=blood', 'urea nitrogen; CD4=cluster of differentiation 4; eGFR=estimated glomerular filtration rate; FIX=factor IX;', 'FVIII=factor VIII; GGT= gamma glutamyl transferase; HAV=hepatitis A virus; HBs Ag=hepatitis B virus surface', 'antigen; HBc=hepatitis B virus core; HCV=hepatitis C virus; HEV=hepatitis E virus; HIV=human', 'immunodeficiency virus; IgG=immunoglobulin G antibody; IgM=immunoglobulin M antibody; INR=International', 'normalized ratio; MDRD=Modification of Diet in Renal Disease; PCR=polymerase chain reaction; RBC=red', 'blood cell; RNA=ribonucleic acid; WBC=white blood cell.', 'a Will not be communicated to investigational sites.', '7.5.5.1. Additional Laboratory Assessments', 'For any safety event or laboratory abnormality, additional laboratory assessments, imaging, and', 'consultation may be performed for clinical evaluation and/or in consultation with the study', 'Medical Monitor; results may be collected and should be included in the clinical database.', 'Additional laboratory assessments will be performed in patients who experience any LFT', 'abnormalities as outlined in Section 6.2.3.1. Following the occurrence of elevated liver', 'transaminases or other LFT abnormalities per central laboratory, all assessments in Table 6 will', 'be performed one time, as well as hematology, serum chemistry, LFT, and coagulation', 'assessments from Table 5, AT levels, and other assessments or evaluations per Investigator', 'discretion, as appropriate.', 'Monitoring and dose modification will also be performed as outlined in Section 6.2.3.1.', 'Property of the Sanofi Group - strictly confidential', '59', '(electronic 1.0)']\n\n###\n\n", "completion": "END"}